Triple-negative breast cancer (TNBC) represents approximately 15% to 20% of all breast cancers and is an especially virulent form of the malignancy. Until recently, treatment options for TNBC were limited, but new therapies have been approved in the past few years and others are in development. This activity focuses on novel options for TNBC, including the role of new and emerging treatment regimens, and the management of toxicities associated with them.
Interactive, audio-enhanced slide lecture
After completing this activity, participants should be better able to:
- Discuss the mechanisms of action of novel available and emerging therapies for TNBC within the context of the underlying tumor biology
- Identify treatment strategies for TNBC based on efficacy, safety, and patient- and disease-related factors
- Implement strategies to identify, monitor, and manage treatment-related adverse events and nonadherence in patients with TNBC
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Course director: Lee Schwartzberg, MD, FACP, West Cancer Center, Germantown, Tennessee
CNE course advisor: Stephanie Andrews, MS, ANP-BC, Moffitt Cancer Center, Tampa, Florida
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until February 27, 2021. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Emilee Thomas, MMS, MPH, PA-C, Weill Cornell Medicine, New York, New York
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity was developed from a series of programs cosupported by educational grants from Astellas; Astellas and Pfizer, Inc; Bristol-Myers Squibb; Celgene Corporation; Eisai Inc; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc, administered by Pharmacyclics, LLC; Taiho Oncology, Inc; and Sanofi Genzyme.
This activity is supported by educational grants from Celgene Corporation and Eisai Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are expected to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Andrews: consultant: Daiichi-Sankyo, OncoSec; speakers bureau: Genentech.
Dr Schwartzberg: consultant: Amgen, AstraZeneca, Pfizer.
Dr Tolaney: advisory board: Celldex, Puma, Sanofi; advisory board/consultant: Paxman; advisory board/study PI: Genentech/Roche, Immunomedics; advisory board/consultant/study PI: AstraZeneca, Bristol-Myers Squibb, Eisai, Lilly, Merck, Nanostring, Nektar, Novartis, Pfizer; consultant: Tesaro; steering committee: Seattle Genetics; study PI: Cyclacel, Exelixis.
None of the members of the CE Alliance staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Watch the eCourse in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: February 28, 2020
Expiration date: February 27, 2021
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 96119OPCE-7A